By Sneha S K
March 26 (Reuters) – Telehealth firm eMed said on Thursday it has raised $200 million in its latest funding round, valuing the Miami, Florida-based company at more than $2 billion.
Backed by seven-time Super Bowl champion Tom Brady, the company partners with employers and government payers to manage GLP-1 usage, a class of obesity and diabetes drugs whose cost has limited broader insurance coverage.
Several telehealth platforms are competing for a share of the booming GLP-1 weight-loss market, which is widely expected to generate $150 billion in annual sales by next decade.
Proceeds from the Series A funding round, led by Aon Consulting, will help advance eMed’s agentic AI platform and support the launch of a healthcare payment model aimed at lowering employer health care costs, the company said
Other prominent investors included Brady, who is also the company’s founding chief wellness officer, CEO Linda Yaccarino, as well as Paragon Biosciences founder and CEO Jeff Aronin, eMed said.
Brady said in a statement that he is investing his time and capital in the company as he believes in eMed’s agentic AI platform and its people and partners.
Founded in 2020, eMed gained traction during the pandemic with at-home COVID-19 tests before expanding into diagnostics for strep throat and urinary tract infections, though it has since moved away from those offerings.
“The raise confirms eMed momentum and establishes us as the definitive company for population health and helping employers break the runaway health care costs and break their cost curve,” eMed CEO Linda Yaccarino, who was the former chief executive of social media platform X, said in an interview on FOX Business Network’s Mornings with Maria.
(Reporting by Sneha S K in Bengaluru; Editing by Leroy Leo)
Comments